Collegium Pharmaceutical (NASDAQ:COLL) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Collegium (COLL) Raises 2025 Revenue Guidance—Is Profitability Momentum Built to Last? [Yahoo! Finance]
Collegium Pharmaceutical (NASDAQ:COLL) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Collegium to Participate in Upcoming Investor Conferences [Yahoo! Finance]